Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Multiple Myeloma 3Lymphoma 3Recurrence 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × marizomib × Clear all
NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated
4 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Celgene

Phase 1 Completed
38 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡